Jump to content

GUD.V - Knight Therapeutics

bz1516

By bz1516
in Investment Ideas

 Share

Recommended Posts

snowball82 Newbie

snowball82

Posted
Posted

The letter to shareholders / 2019 annual report are now available.

 

For those who don't know the story. Jonathan Goodman, CEO started Knight therapeutics after he sold Paladin Lab. With Paladin the average annual return for 19 years has been 27 %.

 

A short letter to shareholders again this year :

 

"We are pleased to report that 2019 marked a transformative year for Knight as we furthered our mission to become a Rest

of World specialty pharmaceutical company. For the last several years we have been patiently seeking an attractive panLatin American specialty pharmaceutical company acquisition opportunity. In 2019, our patience was finally rewarded

with the purchase of a controlling interest in Grupo Biotoscana. Knight now has 700 employees located in 10 Latin

American markets doing exactly what Knight does – making a difference in the health of patients through our innovative

pharmaceutical products.

 

Building our Rest of World Strategy

Knight is now the premiere pan-American (ex-US) specialty pharmaceutical company. With our strong and proven

regional infrastructure across ten countries in Latin America, Knight is best positioned to become the partner of choice

for pharmaceutical and biotech companies looking for a commercialization partner. Every new innovative pharmaceutical

that is in-licensed leverages our robust Latin American platform for the mutual benefit of patients and our shareholders.

 

Advancing our Portfolio of Innovative Products

 

During the year, we continued to work on expanding our pipeline with the in-licensing of Nerlynx® from Puma Biotechnology,

Inc. Trelstar® from DebioPharm and rigosertib from Onconova Therapeutics, Inc.

In addition, we submitted Ibsrela®, Bijuva® and ImvexxyTM to Health Canada and received approval for Netildex® and

Nerlynx®. We also reached agreement with the pan-Canadian Pharmaceutical Alliance paving the way for the public

reimbursement of Probuphine®.

 

Contributing to our Community

Community service is an integral part of Knight’s DNA. In 2019, we participated in the Ride to Conquer Cancer from

Montreal to Quebec City for the sixth year in a row, and over the years our Knights have raised almost $300,000 to support

cancer research. We are also proud to report we achieved 100% of our objectives in our Centraide campaign for the third

consecutive year.

 

Looking Ahead

As we embark onto 2020, we are all facing an unprecedented situation with the COVID-19 pandemic. We are committed

to ensuring the safety of our employees and the uninterrupted supply of our medicines. We are actively working with our

partners to minimize business interruption and to ensure uninterrupted product supply.

While we carefully navigate these uncharted waters, we remain focused on completing our acquisition of 100% of Grupo

Biotoscana and further deploying our strong balance sheet to build a business that we can all be proud of.

 

 

 

Link to comment
Share on other sites
  • Replies 212
  • Created
  • Last Reply

Top Posters In This Topic

Popular Days

Top Posters In This Topic

Popular Days

snowball82 Newbie

snowball82

Posted
Posted

 

 

https://www.globenewswire.com/news-release/2020/04/16/2016954/0/en/Knight-Therapeutics-Inc-Announces-Completion-of-its-Normal-Course-Issuer-Bid.html

 

"Buffett's first rule of buybacks is that they only make sense when a stock is trading for a significant discount to its intrinsic value. As Buffett has said, "Anytime you can buy stock for less than it's worth, it's advantageous to the continuing shareholders ... but it should be by a demonstrable margin.""

 

"....The Company has purchased a total of 12,053,692 common shares, representing approximately 10% of its public float at the commencement of the NCIB. The shares were purchased at an average price of $7.14 per share."

 

So we the long term shareholders own 10 % more without adding a dime.

Link to comment
Share on other sites
snowball82 Newbie

snowball82

Posted
Posted

Antibe Therapeutics Updates Timing for Top-Line Results From Completed

Phase 2B Dose-Ranging, Efficacy Study

 

- Top-line data expected within six weeks -

 

TORONTO--(BUSINESS WIRE)--May 4, 2020--Antibe Therapeutics Inc. (TSXV: ATE,

OTCQB: ATBPF) today provides an update on the timing of top-line results for the Phase 2B

dose-ranging, efficacy study for its lead drug, ATB-346. Involving 360 patients across 40 clinical

sites, this study is one of the largest ever undertaken in Canada. The Company is pleased to

report that its clinical research organization (“CRO”), Veristat, was able to complete the trial and

capture all patient data without compromising the size and integrity of the study. However,

ongoing hospital restrictions, clinic closures and complexities arising from remote working

constraints have slowed Veristat’s data collection, validation and analysis beyond the timeframe

envisioned last month. As a result of these new updates from its CRO, the Company anticipates

the release of top-line results within six weeks. Antibe confirms that it will remain blinded until

Veristat releases these results to the Company.

Dan Legault, Antibe’s CEO, remarked, “Although the world is facing singular challenges in light

of the COVID-19 health crisis, we are fortunate to have successfully completed the collection of

data for every patient enrolled in the study. Validating and processing these data is a non-trivial

task in the current environment, especially given the study’s large number of sites. Although

later than anticipated, we look forward to delivering robust and complete top-line data as soon as

possible.”

The Company has benefited from recent warrant exercise activity and had a cash balance of $6

million as of May 1, 2020. Accordingly, Antibe confirms that it is funded beyond the upcoming

data readout.

 

About ATB-346

ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. Nonsteroidal anti-inflammatory

drugs (“NSAIDs”) are the most commonly used therapy for osteoarthritis, but their use is

associated with a high incidence of gastrointestinal ulceration and bleeding. NSAIDs are also

widely used in conditions such as rheumatoid arthritis, ankylosing spondylitis, gout, and general

pain reduction, with a similarly high rate of gastrointestinal ulceration and bleeding. It is wellaccepted that patients with these conditions would benefit greatly from an effective, nonaddictive, GI-sparing anti-inflammatory/analgesic agent such as ATB-346. The current Phase 2

dose-ranging, efficacy study is designed to validate ATB-346’s effectiveness compared to

placebo in reducing osteoarthritis pain.

Link to comment
Share on other sites
snowball82 Newbie

snowball82

Posted
Posted

MONTREAL, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. ("Knight" or “Offeror”) today announced that, further to its acquisition of a controlling interest (the “Transfer of Control”) in Biotoscana Investments S.A. (“GBT” or “Company”), it has submitted to B3 S.A. – Brasil, Bolsa, Balcão (“B3”) the authorization request to carry out a Unified Tender Offer (as defined below) for the acquisition of all outstanding Brazilian Depositary Receipts – BDRs of GBT (“BDRs”).

 

I guess we should get an update before the AGM.

 

 

Link to comment
Share on other sites
Xerxes Newbie

Xerxes

Posted
Posted

Hey snowball

 

I held GUD since it came out now 4-5 years. Didn’t do too much. But I am Happy to hold it as it gains intrinsic value while going nowhere.

 

I am glad at least someone here is following this thing.

Link to comment
Share on other sites
  • 3 weeks later...
Gregmal Newbie

Gregmal

Posted
Posted

Curious if anyone here has looked at SWK Holdings? Seems as if there'd be some overlap with this type of business. Trades well below book. Making some optical improvements that benefits shareholders, and could possibly get a Russell inclusion bump.

Link to comment
Share on other sites
  • 2 weeks later...
snowball82 Newbie

snowball82

Posted
Posted

Interesting days to come for Knight therapeutics.

 

AGM tomorow

 

Q1 results Friday

 

https://www.globenewswire.com/news-release/2020/06/18/2050479/0/en/Notice-of-Knight-Therapeutics-First-Quarter-2020-Results-Conference-Call.html

 

Grupo Biotoscana Q1 results Friday

 

https://api.mziq.com/mzfilemanager/v2/d/f78739c6-0e47-4145-8a2e-947b5835a922/a070974b-0187-6138-7d77-fc03944c8ce2?origin=1

 

Expectations are likely low with the pandemic and the brazilian real but who knows. What are your expectations ?

 

 

 

 

 

 

Link to comment
Share on other sites
snowball82 Newbie

snowball82

Posted
Posted

Interesting days to come for Knight therapeutics.

 

AGM tomorow

 

Q1 results Friday

 

https://www.globenewswire.com/news-release/2020/06/18/2050479/0/en/Notice-of-Knight-Therapeutics-First-Quarter-2020-Results-Conference-Call.html

 

Grupo Biotoscana Q1 results Friday

 

https://api.mziq.com/mzfilemanager/v2/d/f78739c6-0e47-4145-8a2e-947b5835a922/a070974b-0187-6138-7d77-fc03944c8ce2?origin=1

 

Expectations are likely low with the pandemic and the brazilian real but who knows. What are your expectations ?

 

Very good question Snowball!

 

Here some info from a new report:

 

‪ “Street estimates for Q1 are for sales of $55 million and EBITDA of ~$5 million (nine per cent margin) and near our estimates. We see the forecasts for Q1 as valid with COVID-19 potentially impacting Q2 with large exposure to the Brazil market (56 per cent of GBT’s sales). However, we also see resilience in GBT’s therapeutic areas, including Onco& Onco-Hematology (43 per cent of sales) and infectious diseases (36 per cent of sales),” Keywood wrote.

 

“The bar is low as well in our view on a year-over-year basis with a small operating business in Canada prior, relative to the capital structure. Although some caution is always prudent, given the current environment, we remain bullish on Knight and ahead of Q1 considering the overall reward to risk profile, including $400 million in cash,” Keywood wrote.

 

https://www.cantechletter.com/2020/06/knight-therapeutics-q1-stifel/

Link to comment
Share on other sites
valueinvestor Newbie

valueinvestor

Posted
Posted

;)

 

You're the unsung hero of COBF. The hero COBF deserves, but doesn't need.

 

Always admired Jonathan and you, who kept us up-to-date and probably bought more into what seems a perpetually cheap stock. I always read your posts, and hopefully you don't stop because of the lack of response. Reason why I don't is because there's nothing to add - Jonathan was clear. It's going to take at least a decade to play out, Paladin took a decade to get to an inflection point before the stock ripped upward. It seems Knight is getting to the same track, or possibly shorter because of COVID-19.

 

Question: Why are you still invested? I was invested when they had the voucher, and got out afterwards, but never saw a reason to get in relative to other companies. I still think their acquisition will still need time to be digested, and more capital must be deployed to move the needle. They definitely have a precious baby in the making, but nine months is still needed for delivery. Do you see any catalyst or is it an alternative to cash?

Link to comment
Share on other sites
snowball82 Newbie

snowball82

Posted
Posted

;)

 

You're the unsung hero of COBF. The hero COBF deserves, but doesn't need.

 

Always admired Jonathan and you, who kept us up-to-date and probably bought more into what seems a perpetually cheap stock. I always read your posts, and hopefully you don't stop because of the lack of response. Reason why I don't is because there's nothing to add - Jonathan was clear. It's going to take at least a decade to play out, Paladin took a decade to get to an inflection point before the stock ripped upward. It seems Knight is getting to the same track, or possibly shorter because of COVID-19.

 

Question: Why are you still invested? I was invested when they had the voucher, and got out afterwards, but never saw a reason to get in relative to other companies. I still think their acquisition will still need time to be digested, and more capital must be deployed to move the needle. They definitely have a precious baby in the making, but nine months is still needed for delivery. Do you see any catalyst or is it an alternative to cash?

 

Thank you. I think it takes time to build a ROW platform with the right synergistic specialties. The opportunities are where the large pharmas don’t chase.

 

I still have to read all the Q1 results.

 

https://www.globenewswire.com/news-release/2020/06/26/2053988/0/en/Knight-Therapeutics-Reports-First-Quarter-2020-Results.html

 

Link to comment
Share on other sites
Spekulatius Newbie

Spekulatius

Posted
Posted

Been following this for a while, the cheapskate I am. Some not so original thoughts:

Biotoscana seems like a dog - low gross margins, SA exposure, mostly licensed drugs

 

What are these little deals where they spent a few thousand $ on deals? Is any of this likely to move the needle? why even bother ? My guess sooner or later this company will create some value with an interesting deal but right now it looks like a value trap.

 

Again, I also want to thank snowball82 to keep this on our radar screen.

Link to comment
Share on other sites
snowball82 Newbie

snowball82

Posted
Posted

MONTREAL, July 08, 2020 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) and its wholly owned subsidiary 1178991 CANADA INC. ("Knight" or “Offeror”) today announced that the Brazilian Securities and Exchange Commission (Comissão de Valores Mobiliários) (“CVM”) has approved the Tender Offer process filed by 1178991 CANADA INC. for the acquisition of all outstanding Brazilian Depositary Receipts (“BDRs”) of Biotoscana Investments S.A. (“GBT” or “Company”).

 

 

https://www.globenewswire.com/news-release/2020/07/08/2059598/0/en/Knight-Therapeutics-Announces-CVM-Approval-of-the-Tender-Offer-for-remaining-48-8-of-Grupo-Biotoscana.html

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share
Go to topic listing


×
×
  • Create New...